Log in
Sign up
Golden has been acquired by ComplyAdvantage.Read about it here ⟶
‌

US Patent 10322174 Neutralizing anti-TL1A monoclonal antibodies

Patent 10322174 was granted and assigned to Cedars-Sinai Medical Center on June, 2019 by the United States Patent and Trademark Office.

OverviewStructured DataIssuesContributorsActivity
Is a
Patent
Patent
0
Current Assignee
Cedars-Sinai Medical Center
Cedars-Sinai Medical Center
0
Date Filed
October 24, 2017
0
Date of Patent
June 18, 2019
0
Patent Applicant
Cedars-Sinai Medical Center
Cedars-Sinai Medical Center
0
Patent Application Number
15792266
0
Patent Citations Received
‌
US Patent 12110555 Diagnosis and treatment of inflammatory bowel disease
0
‌
US Patent 11268149 Diagnosis and treatment of inflammatory bowel disease
‌
US Patent 11292848 Humanized antibodies to TNF-like ligand 1A (TL1A) and uses thereof
‌
US Patent 11312768 Signature of TL1A (TNFSF15) signaling pathway
‌
US Patent 11440954 Optimized anti-TL1A antibodies
‌
US Patent 11999789 Humanized antibodies to TNF-like ligand 1A (TL1A) and uses thereof
0
‌
US Patent 12084722 Methods of determining responsiveness to anti-TNFα therapy in inflammatory bowel disease
0
‌
US Patent 11236393 Methods of determining responsiveness to anti-TNFα therapy in inflammatory bowel disease
‌
US Patent 10689439 Optimized anti-TL1A antibodies
Patent Inventor Names
Bradley Henkle
0
Janine Bilsborough
0
Stephan Targan
0
Patent Jurisdiction
United States Patent and Trademark Office
United States Patent and Trademark Office
0
Patent Number
10322174
0
Patent Primary Examiner
‌
Bridget E Bunner
0

Find more entities like US Patent 10322174 Neutralizing anti-TL1A monoclonal antibodies

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo